Literature DB >> 21417236

Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.

Marion Flipo1, Matthieu Desroses, Nathalie Lecat-Guillet, Bertrand Dirié, Xavier Carette, Florence Leroux, Catherine Piveteau, Fatma Demirkaya, Zoé Lens, Prakash Rucktooa, Vincent Villeret, Thierry Christophe, Hee Kyoung Jeon, Camille Locht, Priscille Brodin, Benoit Déprez, Alain R Baulard, Nicolas Willand.   

Abstract

We report in this article an extensive structure-activity relationships (SAR) study with 58 thiophen-2-yl-1,2,4-oxadiazoles as inhibitors of EthR, a transcriptional regulator controling ethionamide bioactivation in Mycobacterium tuberculosis. We explored the replacement of two key fragments of the starting lead BDM31343. We investigated the potency of all analogues to boost subactive doses of ethionamide on a phenotypic assay involving M. tuberculosis infected macrophages and then ascertained the mode of action of the most active compounds using a functional target-based surface plasmon resonance assay. This process revealed that introduction of 4,4,4-trifluorobutyryl chain instead of cyanoacetyl group was crucial for intracellular activity. Replacement of 1,4-piperidyl by (R)-1,3-pyrrolidyl scaffold did not enhance activity but led to improved pharmacokinetic properties. Furthermore, the crystal structures of ligand-EthR complexes were consistent with the observed SAR. In conclusion, we identified EthR inhibitors that boost antibacterial activity of ethionamide with nanomolar potency while improving solubility and metabolic stability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21417236     DOI: 10.1021/jm200076a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition.

Authors:  Michelle Lay Teng Ang; Siti Zarina Zainul Rahim; Zarina Zainul Rahim Siti; Guanghou Shui; Petronela Dianiškova; Jan Madacki; Wenwei Lin; Vanessa Hui Qi Koh; Julia Maria Martinez Gomez; Sukumar Sudarkodi; Anne Bendt; Markus Wenk; Katarína Mikušová; Jana Korduláková; Kevin Pethe; Sylvie Alonso
Journal:  Infect Immun       Date:  2014-02-24       Impact factor: 3.441

2.  Rubrolone production by Dactylosporangium vinaceum: biosynthesis, modulation and possible biological function.

Authors:  Sophie Moureu; Thibault Caradec; Xavier Trivelli; Hervé Drobecq; Delphine Beury; Peggy Bouquet; Segolene Caboche; Eva Desmecht; Florence Maurier; Ghaffar Muharram; Baptiste Villemagne; Adrien Herledan; David Hot; Nicolas Willand; Ruben Christiaan Hartkoorn
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-30       Impact factor: 4.813

Review 3.  Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.

Authors:  Kerstin A Wolff; Liem Nguyen
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091

Review 4.  New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.

Authors:  E Jeffrey North; Mary Jackson; Richard E Lee
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands.

Authors:  Xavier Carette; Nicolas Blondiaux; Eve Willery; Sylviane Hoos; Nathalie Lecat-Guillet; Zoé Lens; Alexandre Wohlkönig; René Wintjens; Sameh H Soror; Frédéric Frénois; Bertrand Dirié; Vincent Villeret; Patrick England; Guy Lippens; Benoit Deprez; Camille Locht; Nicolas Willand; Alain R Baulard
Journal:  Nucleic Acids Res       Date:  2011-12-09       Impact factor: 16.971

6.  Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.

Authors:  Phuong Chi Nguyen; Vincent Delorme; Anaïs Bénarouche; Benjamin P Martin; Rishi Paudel; Giri R Gnawali; Abdeldjalil Madani; Rémy Puppo; Valérie Landry; Laurent Kremer; Priscille Brodin; Christopher D Spilling; Jean-François Cavalier; Stéphane Canaan
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

7.  EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide.

Authors:  Michelle L T Ang; Siti Z Zainul Rahim; Paola Florez de Sessions; Wenwei Lin; Vanessa Koh; Kevin Pethe; Martin L Hibberd; Sylvie Alonso
Journal:  Front Microbiol       Date:  2017-04-25       Impact factor: 5.640

8.  Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.

Authors:  Petar O Nikiforov; Michal Blaszczyk; Sachin Surade; Helena I Boshoff; Andaleeb Sajid; Vincent Delorme; Nathalie Deboosere; Priscille Brodin; Alain R Baulard; Clifton E Barry; Tom L Blundell; Chris Abell
Journal:  ACS Chem Biol       Date:  2017-04-05       Impact factor: 5.100

9.  A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.

Authors:  Petar O Nikiforov; Sachin Surade; Michal Blaszczyk; Vincent Delorme; Priscille Brodin; Alain R Baulard; Tom L Blundell; Chris Abell
Journal:  Org Biomol Chem       Date:  2016-01-25       Impact factor: 3.876

Review 10.  Targeting Antibiotic Resistance.

Authors:  Mathieu F Chellat; Luka Raguž; Rainer Riedl
Journal:  Angew Chem Int Ed Engl       Date:  2016-03-22       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.